Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3647 | Small Gift Wiki | 1.00 |
| drug3036 | Postcard Wiki | 0.71 |
| drug1047 | Convalescent Plasma Wiki | 0.19 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
In this evaluation, 3 different versions of mailers promoting annual mammograms are being sent to women on the month of their 50th and 64th birthdays. The researchers hypothesize that the use of behavioral nudges in the mailers should lead to increased uptake in mammogram screening.
Description: Binary variable indicating whether a mammogram was completed
Measure: Mammogram Completion at 6 months (2020) Time: 6 months from intervention start dateDescription: Binary variable indicating whether a mammogram was completed (a longer time frame allows for late responses)
Measure: Mammogram Completion at 12 months (2020) Time: 12 months from intervention start dateDescription: Number of visits (proxy for increased preventative health care)
Measure: Primary Care Provider Visits at 6 months (2020) Time: 6 months from intervention start dateDescription: Number of visits (proxy for increased preventative health care)
Measure: Primary Care Provider Visits at 12 months (2020) Time: 12 months from intervention start dateDescription: Number of visits (proxy for increased preventative health care)
Measure: Obstetrician-Gynecologist Visits at 6 months (2020) Time: 6 months from intervention start dateDescription: Number of visits (proxy for increased preventative health care)
Measure: Obstetrician-Gynecologist Visits at 12 months (2020) Time: 12 months from intervention start dateDescription: Binary variable indicating whether the recipient was diagnosed with breast cancer
Measure: Breast Cancer Diagnosis at 6 months (2020) Time: 6 months from intervention start dateDescription: Binary variable indicating whether the recipient was diagnosed with breast cancer
Measure: Breast Cancer Diagnosis at 12 months (2020) Time: 12 months from intervention start dateDescription: Number of Emergency Department Visits (proxy for increased costly utilization of health system resources)
Measure: Emergency Department Visits at 6 months (2020) Time: 6 months from intervention start dateDescription: Number of Emergency Department Visits (proxy for increased costly utilization of health system resources)
Measure: Emergency Department Visits at 12 months (2020) Time: 12 months from intervention start dateDescription: Binary variable indicating whether a mammogram was completed to be used for exploratory pre-post comparisons
Measure: Mammogram Completion at 12 months (2019) Time: 12 months from 2019 intervention start dateDescription: Number of visits to be used for exploratory pre-post comparisons (proxy for increased preventative health care)
Measure: Primary Care Provider Visits at 12 months (2019) Time: 12 months from 2019 intervention start dateDescription: Binary variable indicating whether the woman was diagnosed with breast cancer
Measure: Breast Cancer Diagnosis at 12 months (2019) Time: 12 months from 2019 intervention start dateDescription: Number of Emergency Department Visits (proxy for increased costly utilization of health system resources)
Measure: Emergency Department Visits at 12 months (2019) Time: 12 months from 2019 intervention start dateAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports